ADC Therapeutics SA (ADCT) Revenue & Revenue Breakdown
ADC Therapeutics SA Revenue Highlights
Latest Revenue (Y)
$69.56M
Latest Revenue (Q)
$17.41M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
ADC Therapeutics SA Revenue by Period
ADC Therapeutics SA Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $69.56M | -66.86% |
2022-12-31 | $209.91M | 518.89% |
2021-12-31 | $33.92M | 100.00% |
2020-12-31 | - | -100.00% |
2019-12-31 | $2.34M | 105.26% |
2018-12-31 | $1.14M | -36.77% |
2017-12-31 | $1.80M | - |
ADC Therapeutics SA Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $17.41M | -3.56% |
2024-03-31 | $18.05M | 7.52% |
2023-12-31 | $16.79M | 15.85% |
2023-09-30 | $14.49M | -24.84% |
2023-06-30 | $19.28M | 1.53% |
2023-03-31 | $18.99M | -72.79% |
2022-12-31 | $69.80M | -8.55% |
2022-09-30 | $76.32M | 341.39% |
2022-06-30 | $17.29M | -62.81% |
2022-03-31 | $46.50M | 173.36% |
2021-12-31 | $17.01M | 29.38% |
2021-09-30 | $13.15M | 249.65% |
2021-06-30 | $3.76M | 100.00% |
2021-03-31 | - | -100.00% |
2020-12-31 | $51.90M | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | -100.00% |
2019-06-30 | $1.96M | 67.69% |
2019-03-31 | $1.17M | 354.37% |
2018-12-31 | $257.50K | - |
2018-09-30 | $257.50K | -17.60% |
2018-06-30 | $312.50K | - |
2018-03-31 | $312.50K | - |
ADC Therapeutics SA Revenue Breakdown
ADC Therapeutics SA Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 22 | Dec 21 |
---|---|---|---|
Royalty Revenue | $498.00K | - | - |
Product | $69.06M | - | - |
License Revenues | - | - | - |
Contract Revenue | - | $135.00M | - |
Product Revenue | - | $74.91M | $33.92M |
Latest
Quarterly Revenue by Product
Product/Service | Sep 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 |
---|---|---|---|---|---|---|---|---|
Product | $18.02M | $17.85M | - | - | - | - | - | - |
Royalty Revenue | $448.00K | $205.00K | $373.00K | $86.00K | $39.00K | - | - | - |
Product Revenue, Net | - | - | - | $19.20M | $18.95M | $21.32M | $17.29M | $16.50M |
License Revenue | - | - | - | - | - | $55.00M | - | $30.00M |
Latest
ADC Therapeutics SA Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 23 |
---|---|
UNITED STATES | $69.06M |
EMEA | $498.00K |
JAPAN | - |
Latest
Quarterly Revenue by Country
Country | Sep 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 |
---|---|---|---|---|---|
UNITED STATES | $18.02M | $17.85M | $30.91M | $19.20M | $18.95M |
EMEA | $448.00K | $205.00K | $373.00K | $86.00K | $39.00K |
JAPAN | - | - | - | - | - |
Latest
ADC Therapeutics SA Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
RARE | Ultragenyx Pharmaceutical | $434.25M | $147.03M |
ALEC | Alector | $97.06M | $15.08M |
ARVN | Arvinas | $78.50M | $102.40M |
ADCT | ADC Therapeutics SA | $69.56M | $17.41M |
PTGX | Protagonist Therapeutics | $60.00M | $4.67M |
AADI | Aadi Bioscience | $24.35M | $7.21M |
RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
RNA | Avidity Biosciences | $9.56M | $2.04M |
STOK | Stoke Therapeutics | $8.78M | $4.89M |
GBIO | Generation Bio | $5.90M | $4.09M |
CRNX | Crinetics Pharmaceuticals | $4.01M | - |
IPSC | Century Therapeutics | $2.23M | $791.00K |
FIXX | Q32 Bio | $1.16M | - |
DSGN | Design Therapeutics | - | - |
ALVR | AlloVir | - | - |
ALXO | ALX Oncology | - | - |
BDTX | Black Diamond Therapeutics | - | - |
KURA | Kura Oncology | - | - |
PASG | Passage Bio | - | - |
AKRO | Akero Therapeutics | - | - |